The choice of the antihypertensive drug in special conditions: evidence-based data in co-morbid neurology diseases (part 5)
https://doi.org/10.18705/1607-419X-2015-21-2-116-120
Abstract
Hypertension is a risk factor for some neurological disorders (like stroke, transient ischemic attack, cognitive dysfunction, including the most severe forms, such as dementia). In other diseases of neurology system systemic hypertension might either contribute to the progression of the disease, or decrease the treatment efficiency. Thus, the management of hypertension in a patient with co-morbid neurological disorder is a complex task requiring the comprehensive approach and the joint efforts of both cardiologist and neurologist. This will result in the best control of hypertension and the most efficient risk reduction. The current guidelines on diagnostics, management and prevention of hypertension (by the Joint National Committee of the USA, European Society of Cardiology / European Society of Hypertension, American Society of Hypertension / International Society of Hypertension, and national guidelines by Russian Society of Cardiology) consider some issues of the management of a hypertensive patient with concomitant neurology disorder (mainly, stroke, and transient ischemic attack). The paper shows the evidence-based data on the hypertension management in co-existent neurodegenerative diseases, cognitive dysfunction, neuromuscular diseases, epilepsy, migraine etc.
About the Authors
L. S. Korostovtseva
Federal North-West Medical Research Centre, St Petersburg, Russia
Russian Federation
Russian Federation
MD, PhD, Researcher, Research Department for Hypertension, Somnology Group, Federal North-West Medical Research Centre;
N. E. Zvartau
Federal North-West Medical Research Centre, St Petersburg, Russia
Russian Federation
Russian Federation
MD, PhD, Senior Researcher, Research Department for Hypertension, Research Laboratory of Pathogenesis and Therapy of Hypertension, Federal North-West Medical Research Centre;
E. R. Barantsevich
Federal North-West Medical Research Centre, St Petersburg, Russia
Russian Federation
Russian Federation
MD, PhD, Professor, Head, Research Department for Neurology, Federal North-West Medical Research Centre;
A. O. Konradi
Federal North-West Medical Research Centre, St Petersburg, Russia
Russian Federation
Russian Federation
MD, PhD, Professor, Head, Research Department for Hypertension, Director General of Science, Federal North-West Medical Research Centre.
References
1. James PA, Oparil S, Carter BL, Cushman WC, DennisonHimmelfarb C, Handler J et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). J Am Med Assoc. 2014;311(5): 507–520.
2. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American society of hypertension and the International society of hypertension. J Hypertens. 2014;32(1):3–15.
3. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31 (7):281–357.
4. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. 2011;10 (6, прил.). 64 с. [National guidelines on cardiovascular prevention. Kardovskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2011;10 (6, suppl.). 64 p. In Russian].
5. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1587.
6. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033–1041.
7. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: metaanalysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J. 2009;338: b1665.
8. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectivelydesigned overviews of randomised trials. Lancet. 2003;362(9395):1527–1535.
9. VerdecchiaP,ReboldiG,AngeliF,GattobigioR,BentivoglioM, Thijs L et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46(2):386–392.
10. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVETCOG): a double-blind, placebo controlled trial. Lancet Neurology. 2008;7(8):683–689.
11. Dufouil C, Godin O, Chalmers J, Coskun O, McMahon S, Tzourio-Mazoyer N et al. Severe cerebral white matter hypersensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke. 2009;40(6):2219–2221.
12. Godin O, Tsourio C, Maillard P, Mazoyer B, Dufouil C. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study. Circulation. 2011;123(3):266–273.
13. Schneider P, Buerger K, Teipel S, Uspenskaya O, Hartmann O, Hansson O et al. Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. Biol Psychiatry. 2011;70(2):145–151.
14. Rodgers JE, Patterson JH. Angiotensin II-receptor blockers: clinical relevance and therapeutic role. Am J Health Syst Pharm. 2001;58(8):671–683.
15. Schrander J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention (MOSES study). Stroke. 2005;36(6):1218–1226.
16. Petrella RJ, Shlyakhto EV, Konradi AO, Berrou JP, Sedefdjian A, Pathak A. OSCAR Publication Group. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study. J Clin Hypertens (Greenwich). 2012;14(2):78–84.
17. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis. 2011;26(4):699–708.
18. Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatr Gerontol Int. 2012;12(2):207–214.
19. Anekonda TS, Quinn JF, Harris C, Frahler K, Wadsworth TL, Woltjer RL. L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiol Dis. 2011;41(1):62–70.
20. Kettenmann B, Feichtinger M, Tilz C, Kaltenhäuser M, Hummel C, Stefan H. Comparison of clonidine to sleep deprivation in the potential to induce spike or sharp-wave activity. Clin Neurophysiol. 2005;116(4):905–912.
21. Liu WS, Petty WC, Jeppsen A, Wade, EJ, Pace, NL. Attenuation of hemodynamic and hormonal responses to ECT with propranolol, Xylocaine, sodium nitroprusside or clonidine. Anesth Analg. 1984;63:244.
22. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337–1345.
23. Pascuzzi RM. Medications and myasthenia gravis (a reference for health care professionals). — [Electronic resource]. URL: http://www.myasthenia.org/LinkClick. aspx?fileticket=JuFvZPPq2vg %3D
24. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L et al. Care considerations working group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9 (2):177–189.
25. Johansen A, Holmen J, Stewart R, Bjerkeset O. Anxiety and depression symptoms in arterial hypertension: the influence of antihypertensive treatment. the HUNT study, Norway. Eur J Epidemiol. 2012;27(1):63–72.
Review
For citations:
Korostovtseva L.S., Zvartau N.E., Barantsevich E.R., Konradi A.O. The choice of the antihypertensive drug in special conditions: evidence-based data in co-morbid neurology diseases (part 5). "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2015;21(2):116-120. (In Russ.) https://doi.org/10.18705/1607-419X-2015-21-2-116-120
Views:
1438
Email this article 